A double-blind randomized multicentre clinical trial to evaluate the efficacy and safety of two doses of etomoxir in comparison with placebo in patients with moderate congestive heart failure: The ERGO (etomoxir for the recovery of glucose oxidation) study

Clinical Science

Volumn 113, Issue 3-4, 2007, Pages 205-212

  Holubarsch, Christian J F ^a   Rohrbach, Martin ^b   Karrasch, Matthias ^b   Boehm, Erich ^b   Polonski, Lech ^c   Ponikowski, Piotr ^d   Rhein, Siegfried ^e  

^a MEDIAN Kliniken GmbH   (Germany)

^b MediGene AG   (Germany)

^c MEDICAL UNIVERSITY OF SILESIA   (Poland)

^d UNIVERSITY OF WROC AW   (Poland)

^e Associated Medical Clinical Science Services   (Poland)

Author keywords

Carnitine palmitoyltransferase 1 (CPT1); Congestive heart failure; Energy metabolism; Etomoxir; Fatty acid; Glucose

Indexed keywords

AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ETOMOXIR; NITRATE; PLACEBO; SPIRONOLACTONE;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GLUCOSE OXIDATION; HEART ARRHYTHMIA; HEART FAILURE; HEART VENTRICLE TACHYCARDIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TESTIS TUMOR;

ADULT; AGED; AGED, 80 AND OVER; CARNITINE O-PALMITOYLTRANSFERASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ENZYME INHIBITORS; EPOXY COMPOUNDS; EXERCISE TEST; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; LIVER; MALE; MIDDLE AGED; STROKE VOLUME; TREATMENT OUTCOME;

EID: 34547800233     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.42/CS20060307     Document Type: Article

References (47)

1. Ho, K., Pinsky, J., Kannel, W. et al. (1993) The epidemiology of heart failure: the Framingham study. J. Am. Coll. Cardiol. 22, (Suppl. A), 6A-13A
2. McMurray, J., Hart, W. and Rhodes, G. (1993) An evaluation of the cost of heart failure to the National Health Service in the UK. Br. J. Med. Econ. 285, 99-110
3. Andrews, R. and Cowley, A. J. L. (1995) Clinical and economic factors in the treatment of congestive heart failure. PharmacoEconomics 7, 119-127
4. Mostered, A., Hoes, A. W., de Bruyne, M. C. et al. (1999) Prevalence of heart failure and left ventricular dysfunction in the general population: The Rotterdam Study. Eur. Heart J. 20, 447-455
5. Murray, C. J. and Lopez, A. D. (1997) Global mortality, disability and the contribution of risk factors: Global Burden of Disease Study. Lancet 349, 1436-1442
6. Cohen-Solal, A., Desnos, M., Delahaye, F. et al. (2000) for the myocardial and heart failure working group of the French Society of Cardiology, the National College of General Hospital Cardiologists and the French Geriatrics Society. A national survey of heart failure in French hospitals. Eur. Heart J. 21, 763-769
7. Taubert, G., Bergmeier, C., Andersen, H. et al. (2001) Clinical profile and management of heart failure: rural community hospital vs metropolitan heart center. Eur. J. Heart Failure 3, 611-617
8. ACC/AHA Task Force (1995) Guidelines for the evaluation and management of heart failure. Report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (committee on evaluation and management heart failure). Circulation 92, 2764-2784
9. Packer, M., Gheorghiade, M., Young, J. B. et al. (1993) for the RADIANCE Study. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting (enzyme inhibitors). N. Engl. J. Med. 329, 1-7
10. Pitt, B., Zannad, F., Remme, W. J. et al. (1999) RALES-study. N. Engl. J. Med. 341, 709-717
11. Pitt, B., Remme, W. J., Zannad, F. et al. (2003) Eplerenone post-AMI heart failure efficacy and survival study: primary results of the EPHESUS-trial. N. Engl. J Med. 348, 1309-1321
12. The Digitalis Investigation Group (1997) The effect of digoxin on mortality and morbidity in patients with heart failure.N. Engl. J. Med. 336, 525-533
13. Cohn, J. N., Johnson, G., Ziesche, S. et al. (1991) A comparison of enalapril with hydralazinisosorbide dinitrate in the treatment of chronic congestive heart failure. N. Engl. J. Med. 325, 303-310
14. The SOLVD investigators (1991) Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N. Engl. J. Med. 325, 293-302
15. Pfeffer, M. A., Braunwald, E., Moye, L. A. et al. (1992) Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. N. Engl. J. Med. 327, 669-677
16. The Acute Infarction Ramipril Efficacy (AIRE) Study investigators (1993) Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 342, 821-828
17. Packer, M., Bristow, M. R., Cohn, J. N. et al. (1996) The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N. Engl. J. Med. 334, 1349-1355
18. Packer, M., Coats, A. S. J., Fowler, M. B. et al. (2001) Effect of carvedilol on survival in severe chronic heart failure. N. Engl. J. Med. 344, 1651-1658
19. CIBIS-II Investigators and Committees (1999) The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomized trial. Lancet 353, 9-13
20. MERIT-HF Study Group (1999) Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353, 2001-2007
21. Wolf, H. P. O. (1990) Aryl-substituted 2-oxirane carboxylic acids: a new group of antidiabetic drugs. In New Antidiabetic Drugs (Bailey, C. J. and Flatt, P. R., eds.), pp. 217-229, Smith-Gordon, London
22. Vetter, R. and Rupp, H. (1994) CPT-1 inhibition by etomoxir has a chamber-related action on cardiac sarcoplasmic reticulum and isomyosins. Am. J. Physiol. 267, H2091-H2099
23. Vetter, R., Kott, M. and Rupp, H. (1995) Differential influences of carnitine palmitoyltransferase-1 inhibition and hyperthyroidism on cardiac growth and sacroplasmic reticulum phosphorylation. Eur. Heart J. 16, (Suppl. C), 15-19
24. Rupp, H., Schulze, W. and Vetter, R. (1995) Dietary medium-chain triglycerides can prevent changes in myosin and SR due to CPT-1 inhibition by etomoxir. Am. J. Physiol. 269, R630-R640
25. Rupp, H., Elimban, V. and Dhalla, N. S. (1992) Modification of subcellular organelles in pressure-overloaded heart by etomoxir, a carnitine palmitoyltransferase 1 inhibitor. FASEB J. 6, 2349-2353
26. Zarain-Herzberg, A., Rupp, H., Elimban, V. and Dhalla, N. S. (1996) Modification of sarcoplasmic reticulum gene expression in pressure overload cardiac hypertrophy by etomoxir. FASEB J. 10, 1303-1309
27. Schmidt-Schweda, S. and Holubarsch, C. (2000) First clinical trial with etomoxir in patients with chronic congestive heart failure. Clin. Sci. 99, 27-35
28. 2+-ATPase gene. Circ. Res. 71, 9-17
29. Morita, E., Yasue, H., Yoshimura, M. et al. (1995) Increased plasma levels of brain natriuretic peptide in patients with acute myocardial infarction. Circulation 88, 82-91
30. Hama, No., Itoh, H., Shirakama, G. et al. (1995) Rapid ventricular induction of brain natriuretic peptide gene expression in experimental acute myocardial infarction. Circulation 92, 1558-1564
31. Wiese, S., Breyer, T., Dragan, A. et al. (2000) Gene expression of brain natriuretic peptide in isolated atrial and ventricular human myocardium: influence of angiotensin II and fiber length. Circulation 102, 3074-3079
32. Nakao, K., Saito, Y., Itoh, H. et al. (1996) Roles of natriuretic peptides in heart failure. J. Card. Failure 2, 129-133
33. Alpert, N. R. and Mulieri, L. A. (1982) Increased myothermal economy of isometric force generation in compensated cardiac hypertrophy induced by pulmonary artery constriction in rabbit. A characterization of heat liberation in normal and hypertrophied right ventricular papillary muscle. Circ. Res. 50, 491-500
34. Holubarsch, C., Litten, R. Z., Mulieri, L. A. and Alpert, N. R. (1995) Energetic changes of myocardium as an adaptation to chronic hemodynamic overload and thyroid gland activity. Basic Res. Cardiol. 80, 582-593
35. Holubarsch, C., Goulette, R. P., Litten, R. Z. et al. (1985) The economy of isometric force development, myosin isoenzyme pattern and myofibrillar ATPase activity in normal and hypothyroid rat myocardium. Circ. Res. 56, 78-86
36. Hasenfuss, G., Mulieri, L. A., Blanchard, E. M. et al. (1991) Energetics of isometric force development in control and volume-overload human myocardium. Comparison with animal species. Circ. Res. 68, 836-846
37. 2 myosin isoenzyme ratio. J. Mol. Cell. Cardiol. 20, 679-687
38. 2+-ATPase in failing and nonfailing human myocardium. Circ. Res. 75, 434-442
39. Holubarsch, Ch., Schneider, R., Pieske, B. et al. (1995) Positive and negative inotropic effects of DL-sotalol and D-sotalol in failing and nonfailing human myocardium under physiological experimental conditions. Circulation 92, 2904-2910
40. Pieske, B., Kretschmann, B., Meyer, M. et al. (1995) Alterations in intracellular calcium handling associated with the inverse force-frequency relation in human dilated cardiomyopathy. Circulation 92, 1169-1178
41. Feldmann, A. M., Weinberg, E. O., Rax, P. E. and Lorell, B. H. (1993) Selective changes in cardiac gene expression during compensated hypertrophy and the transition to cardiac decompensation in rats with chronic heart aortic banding. Circ. Res. 73, 184-192
42. Hajjar, R. J., Kang, J. X., Gwathmey, J. K. and Rosenzweig, A. (1996) Physiological effects of adenoviral gene transfer of sarcoplasmic reticulum calcium ATPase in isolated rat myocytes. Circulation 94, (Suppl. I), 89
43. Hajjar, R. J., Kang, J. X., Gwathmey, J. K. and Rosenzweig, A. (1997) Physiological effects of adenoviral gene transfer of sarcoplasmic reticulum calcium ATPase in isolated rat myocytes. Circulation 95, 423-429
44. 2+-ATPase overexpression by adenovirus mediated gene transfer and in transgenic animals. Cardiovasc. Res. 37, 360-366
45. Lopaschuk, G. D., Spaffort, M. A., Davies, N. J. and Wall, S. R. (1990) Glucose and palmitate oxidation in isolated working rat hearts reperfused after a period of transient global ischemia. Circ. Res. 66, 546-553
46. Kantor, P. F., Lucien, A., Kozak, R. and Lopaschuk, P. D. (2000) The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long chain 3-ketoacyl coenzyme A thiolase. Circ. Res. 86, 580-588
47. Tynerir, B., Colak, O., Alatas, O., Besogul, Y., Kural, T. and Aslan, R. (1999) Measurement of troponin T to detect cardioprotective effect of trimetazidine during coronary artery bypass-grafting. Ann. Thorac. Surg. 68, 2173-2176